

Cover Story
Guest Editorial
At a recent NIH study section that I chaired, we had many applications that we reviewed as a group before the meeting. At the meeting, we were required to discuss over 50% of the grants.
By Claire Dietz and Matthew Bin Han Ong
Conversation with The Cancer Letter
By Matthew Bin Han Ong and Claire Dietz
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
NCI Trials


NCI Trials for July
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science
- At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.”
















